Bronchial Epithelium of Children With Post-infectious Bronchiolitis Obliterans
Bronchiolitis obliterans (BO) is an irreversible chronic obstructive pulmonary pathology leading to obstruction and/or obliteration of the small airways. In children, the most common form of BO occurs following a serious lower respiratory tract infection. This is a rare complication; the incidence is unknown. The diagn
| Condition(s) | Bronchiolitis Obliterans |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Bronchiolitis obliterans (BO) is an irreversible chronic obstructive pulmonary pathology leading to obstruction and/or obliteration of the small airways. In children, the most common form of BO occurs following a serious lower respiratory tract infection. This is a rare complication; the incidence is unknown. The diagnosis, often late, is made on clinical, spirometric and radiological arguments. The pathophysiology would be linked to damage to the airway epithelium. PIBO is most commonly associated with adenovirus (ADV) infection (serotypes 3, 7, 11 and 21) but also other viruses such as rhinovirus (RV). The treatment of PIBO is not clearly established, it remains empirical. The research hypothesis is that the morphology of the nasal epithelium of children with ADV or RV infection is diffe |
| Who can participate | Inclusion Criteria: 1. Children from 1 month to 6 years hospitalized at the Timone Enfant University Hospital 2. Diagnosis of an adenovirus or rhinovirus respiratory infection confirmed on a nasal swab, made upon arrival as part of the child's initial care 3. Consent form read, understood, approved and signed by parents before any study procedure 4. Affiliation to a social security scheme or beneficiary of such a scheme The inclusion criteria for children who were not hospitalized when diagnosed with an adenovirus and rhinovirus respiratory infection at the Timone Enfant University Hospital are: 1. Children from 1 month to 6 years old transferred to the Timone Enfant University Hospital 2. Show the following signs: has. Clinical: clinical signs persist 6 weeks after a viral infection: tach |
| Ages | 1 Month to 6 Years |
| Sex | All |
| Lead sponsor | Institut National de la Santé Et de la Recherche Médicale, France |
| Locations | Marseille, France |
| Start date | 2023-12-04 |
| NCT ID | NCT06140901 |
| Official listing | https://clinicaltrials.gov/study/NCT06140901 |